Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

Cisplatin (cis-diamminedichloroplatinum (II)) is an effective agent against various solid tumours. Despite its effectiveness, the dose of cisplatin that can be administered is limited by its nephrotoxicity. Hundreds of platinum compounds (e.g. carboplatin, oxaliplatin, nedaplatin and the liposomal form lipoplatin) have been tested over the last two decades in order to improve the effectiveness and to lessen the toxicity of cisplatin. Several agents have been tested to see whether they could ameliorate or augment the nephrotoxicity of platinum drugs. This review summarizes these studies and the possible mechanisms of actions of these agents. The agents that have been shown to ameliorate experimental cisplatin nephrotoxicity include antioxidants (e.g. melatonin, vitamin E, selenium, and many others), modulators of nitric oxide (e.g. zinc histidine complex), agents interfering with metabolic pathways of cisplatin (e.g. procaine HCL), diuretics (e.g. furosemide and mannitol), and cytoprotective and antiapoptotic agents (e.g. amifostine and erythropoietin). Only few of these agents have been tested in humans. Those agents that have been shown to augment cisplatin nephrotoxicity include nitric oxide synthase inhibitors, spironolactone, gemcitabine and others. Combining these agents with cisplatin should be avoided.

Original languageEnglish
Pages (from-to)1173-1183
Number of pages11
JournalFood and Chemical Toxicology
Volume44
Issue number8
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Platinum Compounds
nephrotoxicity
platinum
cisplatin
Cisplatin
Research
oxaliplatin
gemcitabine
spironolactone
Amifostine
procaine
furosemide
erythropoietin
Procaine
Spironolactone
diuretics
Carboplatin
Furosemide
Mannitol
melatonin

Keywords

  • Carboplatin
  • Cisplatin
  • Lipoplatin
  • Nedaplatin
  • Nephrotoxicity
  • Oxaliplatin

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Cite this

@article{b931ac0b83dc49fd9431f401fcbcf0e9,
title = "Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research",
abstract = "Cisplatin (cis-diamminedichloroplatinum (II)) is an effective agent against various solid tumours. Despite its effectiveness, the dose of cisplatin that can be administered is limited by its nephrotoxicity. Hundreds of platinum compounds (e.g. carboplatin, oxaliplatin, nedaplatin and the liposomal form lipoplatin) have been tested over the last two decades in order to improve the effectiveness and to lessen the toxicity of cisplatin. Several agents have been tested to see whether they could ameliorate or augment the nephrotoxicity of platinum drugs. This review summarizes these studies and the possible mechanisms of actions of these agents. The agents that have been shown to ameliorate experimental cisplatin nephrotoxicity include antioxidants (e.g. melatonin, vitamin E, selenium, and many others), modulators of nitric oxide (e.g. zinc histidine complex), agents interfering with metabolic pathways of cisplatin (e.g. procaine HCL), diuretics (e.g. furosemide and mannitol), and cytoprotective and antiapoptotic agents (e.g. amifostine and erythropoietin). Only few of these agents have been tested in humans. Those agents that have been shown to augment cisplatin nephrotoxicity include nitric oxide synthase inhibitors, spironolactone, gemcitabine and others. Combining these agents with cisplatin should be avoided.",
keywords = "Carboplatin, Cisplatin, Lipoplatin, Nedaplatin, Nephrotoxicity, Oxaliplatin",
author = "Ali, {Badreldin H.} and {Al Moundhri}, {Mansour S.}",
year = "2006",
month = "8",
doi = "10.1016/j.fct.2006.01.013",
language = "English",
volume = "44",
pages = "1173--1183",
journal = "Food and Chemical Toxicology",
issn = "0278-6915",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds

T2 - A review of some recent research

AU - Ali, Badreldin H.

AU - Al Moundhri, Mansour S.

PY - 2006/8

Y1 - 2006/8

N2 - Cisplatin (cis-diamminedichloroplatinum (II)) is an effective agent against various solid tumours. Despite its effectiveness, the dose of cisplatin that can be administered is limited by its nephrotoxicity. Hundreds of platinum compounds (e.g. carboplatin, oxaliplatin, nedaplatin and the liposomal form lipoplatin) have been tested over the last two decades in order to improve the effectiveness and to lessen the toxicity of cisplatin. Several agents have been tested to see whether they could ameliorate or augment the nephrotoxicity of platinum drugs. This review summarizes these studies and the possible mechanisms of actions of these agents. The agents that have been shown to ameliorate experimental cisplatin nephrotoxicity include antioxidants (e.g. melatonin, vitamin E, selenium, and many others), modulators of nitric oxide (e.g. zinc histidine complex), agents interfering with metabolic pathways of cisplatin (e.g. procaine HCL), diuretics (e.g. furosemide and mannitol), and cytoprotective and antiapoptotic agents (e.g. amifostine and erythropoietin). Only few of these agents have been tested in humans. Those agents that have been shown to augment cisplatin nephrotoxicity include nitric oxide synthase inhibitors, spironolactone, gemcitabine and others. Combining these agents with cisplatin should be avoided.

AB - Cisplatin (cis-diamminedichloroplatinum (II)) is an effective agent against various solid tumours. Despite its effectiveness, the dose of cisplatin that can be administered is limited by its nephrotoxicity. Hundreds of platinum compounds (e.g. carboplatin, oxaliplatin, nedaplatin and the liposomal form lipoplatin) have been tested over the last two decades in order to improve the effectiveness and to lessen the toxicity of cisplatin. Several agents have been tested to see whether they could ameliorate or augment the nephrotoxicity of platinum drugs. This review summarizes these studies and the possible mechanisms of actions of these agents. The agents that have been shown to ameliorate experimental cisplatin nephrotoxicity include antioxidants (e.g. melatonin, vitamin E, selenium, and many others), modulators of nitric oxide (e.g. zinc histidine complex), agents interfering with metabolic pathways of cisplatin (e.g. procaine HCL), diuretics (e.g. furosemide and mannitol), and cytoprotective and antiapoptotic agents (e.g. amifostine and erythropoietin). Only few of these agents have been tested in humans. Those agents that have been shown to augment cisplatin nephrotoxicity include nitric oxide synthase inhibitors, spironolactone, gemcitabine and others. Combining these agents with cisplatin should be avoided.

KW - Carboplatin

KW - Cisplatin

KW - Lipoplatin

KW - Nedaplatin

KW - Nephrotoxicity

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=33745206033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745206033&partnerID=8YFLogxK

U2 - 10.1016/j.fct.2006.01.013

DO - 10.1016/j.fct.2006.01.013

M3 - Article

C2 - 16530908

AN - SCOPUS:33745206033

VL - 44

SP - 1173

EP - 1183

JO - Food and Chemical Toxicology

JF - Food and Chemical Toxicology

SN - 0278-6915

IS - 8

ER -